TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04078165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zero-Gravity
Description: Free-floating, suspended personal radiation protection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiation protection
Description: Standard lead shields and aprons
Study: NCT04608669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Give paracetamol or placebo and compare temperature

Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol
Description: Give paracetamol or placebo and compare temperature
Study: NCT01261754

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 99mTc MIP 1404
Description: Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1404

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 99mTc MIP 1404
Description: Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1404

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 99mTc MIP 1404
Description: Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1404

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 99mTc MIP 1405
Description: Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1405

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 99mTc MIP 1405
Description: Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1405

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 99mTc MIP 1405
Description: Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1405
Study: NCT01549366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspen Spinous Process Fixation Device
Description: The Aspen device will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pedicle Screws
Description: Pedicle Screws will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
Study: NCT02927743

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: evidence-based online feedback
Description: GPs received during three months weekly mails about evidence-based practice and a small questionnaire to reflect about their practice and the new knowledge
Study: NCT01106027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Eculizumab 900 mg and 1200 mg, administered intravenously (IV)
Study: NCT03715309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: Revlimid 25mg PO d1-10 Plus Rituximab 375 mg/m2 IV d0
Study: NCT04242160

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Clamshell Thoracotomy
Description: Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Clamshell Thoracotomy
Description: Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Left Anterolateral Thoracotomy
Description: Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Left Anterolateral Thoracotomy
Description: Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.
Study: NCT01294683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release (ER) niacin/laropiprant (N/LRPT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release (ER) niacin/laropiprant (N/LRPT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01423253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone 20, 40, or 60 mg/day, orally, once daily (QD) in the evening, with a meal or within 30 minutes after eating, flexibly dosed
Study: NCT03067155

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CMV-specific T cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard anti-viral therapy
Description: Continue with the anti-viral treatment as per standard of care.
Study: NCT02512198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prescription Data Feedback to GP Practices
Description: GP practices will be randomly assigned to receive reports on one of the two topics. They will get these three times at six-monthly intervals. Within the feedback, alongside the patient-level analysis, there will be action-orientated messages to guide the GP practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prescription Data Feedback to GP Practices
Description: GP practices will be randomly assigned to receive reports on one of the two topics. They will get these three times at six-monthly intervals. Within the feedback, alongside the patient-level analysis, there will be action-orientated messages to guide the GP practice.
Study: NCT01372670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Description: Study medications (hydroxyzine/placebo) will be dosed based on participant's weight. Dosing will be according to the following body weight ranges:~15-29 Kg 10 mg TID 30-44 Kg 20 mg TID~≥ 45 Kg 30 mg TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyzine HCL
Description: hydroxyzine HCL dosed on weight given 3x per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given 3 times per day
Study: NCT02696772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy intake
Study: NCT03354741

Intervention type: OTHER
Group type: OTHER
Intervention: laser therapy
Description: stimulation of the acupuncture point P6 by laser therapy

Intervention type: OTHER
Group type: OTHER
Intervention: laser therapy
Description: stimulation of the acupuncture point P6 by laser therapy
Study: NCT02022319

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasonographic Shear Wave Elastography
Study: NCT01051700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034
Description: Investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034
Description: Investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034
Description: Investigational product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01774084

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: PreOp, NutriciaNordica AB

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Water
Study: NCT01504750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic daylight and atmosphere lighting
Description: In the ceiling, luminaires are installed that offer the basic lighting in the patient room that will automatically and gradually change in light level (100-300 lux) and color temperature (3000-4000 K). This so called daily rhythm light meets the EN12464-1 standard for patient rooms in hospitals. The system offers a light boost by bringing the illuminance to a level of maximal 2000 lux and 7000 K, during a period of two hours in the morning. Besides, a low intensity color cove as well as some white LED spots are added to create a pleasant ambience in the patient room. The illuminance is between 50 and 60 lux and, depending on the color choice, the color temperature is 2300 K (relax) or 3800 K (active). The lighting solution used is HealWell of Philips Lighting.
Study: NCT04212988

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Increase the SCO2 value
Description: The interwention process will be started once the SCO2 value below ideal levels (80% of the basic level or 50% of absolute value), by adjusting the position of extracorporeal circulation arteriovenous catheter, balancing arterial pressure, increasing oxygen supply , adjusting pump speed ,etc.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Increase the SCO2 value
Description: The interwention process will be started once the SCO2 value below ideal levels (80% of the basic level or 50% of absolute value), by adjusting the position of extracorporeal circulation arteriovenous catheter, balancing arterial pressure, increasing oxygen supply , adjusting pump speed ,etc.
Study: NCT03619538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: The nefopam group received 120 mg nefopam (Acupan, Pharmbio, France) by continuous iv infusion over the study period (48h)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: The Control group received 120 mg placebo infusion (saline solution) by continuous iv infusion over the study period (48h).
Study: NCT01524341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: KAE609 was supplied as capsules for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: KAE609 was supplied as capsules for oral use.
Study: NCT00568321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN624
Description: 50 mcg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RN624
Description: 200 mcg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01704963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: PCI-32765 will be administered in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be administered before daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.
Study: NCT02437734

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous Coronary Intervention
Description: A phase II, observational, analytical study of coronary angiography and computational fluid dynamics in 100 adults with coronary artery disease undergoing coronary angiography.
Study: NCT01898689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1%
Description: A sciatic catheter was inserted and ropivacaine 0.1% was administered as a basal infusion for 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.1%
Description: A sciatic catheter was inserted and ropivacaine 0.1% was administered as a basal infusion for 6 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.4%
Description: A sciatic catheter was inserted and ropivacaine 0.4% was administered as a basal infusion for 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.4%
Description: A sciatic catheter was inserted and ropivacaine 0.4% was administered as a basal infusion for 6 hours.
Study: NCT01055262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heatwrap 1
Description: 8 hours continuous topically-applied heat
Study: NCT03854396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasterone
Description: Nightly intravaginal prasterone insert (6.5 mg prasterone at a concentration of 0.50%) for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nightly intravaginal placebo insert (Witepsol H-15, a mix of synthetic triglycerides) for 24 weeks.
Study: NCT03051581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/ CT
Description: 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
Study: NCT04556136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standing Phototherapy Kiosk
Description: Benesol is a freestanding booth designed to deliver a small amount of targeted UVB with an interactive user interface and cloud-based software that enables patient self-care. The treatment delivery mechanism uses a metal halide lamp with a series of filters and a lens to optimize full-body exposure to the narrow spectrum (293 - 303nm) of UVB light most efficient at producing vitamin D3. The device uses software to identify patients, establish individual skin types and determine dosage. The system has been designed to manage exposure time and frequency and deliver 60% of a skin-type-adjusted Minimal Erythemal Dose (MED). The expected result for users is a rise in blood levels of 25(OH)D via the endogenous pathway.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D3 Oral supplement
Description: Each subject assigned to the comparison group was instructed to take one vitamin D3 pill, dispensed by the research pharmacist, each day with a meal for 70 days. Subjects were instructed not to take any additional vitamin D supplementation during the study period. This dosing frequency is consistent with the RDA recommendation. Subjects were instructed to bring their pill bottle with them when returning for their follow up appointment.
Study: NCT01793363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tracheotomy
Study: NCT03933397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Specific Protocol
Description: Patients assigned to this treatment protocol will be given pain medicine(s) based on the pain medicine(s) they take at home for pain and what was needed during their past hospital and emergency department visits to treat pain. Medicines will include opioids, either morphine or hydromorphone. A member of the outpatient SCD provider team will review the patient's medical record to determine: 1) the patient's maximum home opioid dose, and 2) previous ED analgesic medication(s) and doses that have been effective and safe in the past. The patient's regular hematologist/sickle cell team will write the treatment plans. Medications will be given every 20-30 minutes for up to 6 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight-based Protocol
Description: Patients assigned to this treatment protocol will be given pain medicine(s) based on their weight. Medicines will include opioids, either morphine or hydromorphone. Plans will be written by the patients regular hematologist/sickle cell team.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 4 mg for participants weighing \<50 kgs, 6mg for participants weighing 50-69.9 kgs, 8mg for participants weighing 70 - 89.9 kgs and 10mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 4 mg for participants weighing \<50 kgs, 6mg for participants weighing 50-69.9 kgs, 8mg for participants weighing 70 - 89.9 kgs and 10mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 1 mg for participants weighing \<60 kgs, 1.5 mg for participants weighing 60 - 89.9 kgs, and 2 mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 1 mg for participants weighing \<60 kgs, 1.5 mg for participants weighing 60 - 89.9 kgs, and 2 mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
Study: NCT01684904

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiation
Study: NCT03732079

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultrasound to measure the IVC diameter. The IVC diameter will be measured in the inspirium and the expirium, and the collapsibility index will be recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultrasound to measure the IVC diameter. The IVC diameter will be measured in the inspirium and the expirium, and the collapsibility index will be recorded.
Study: NCT02576236

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadruple concomitant therapy treatment
Description: Quadruple concomitant therapy treatment:~high dose PPI (Esoméprazole 40 mg X 2 / d- amoxicillin 1gX2 / d - - clarithromycin 500mgX2 / d - metronidazole 500mgX2 / d for 14 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triple therapy guided by the result of the molecular resistance test
Description: Triple therapy guided by the result of the molecular resistance test:~* If clarithromycin S : high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d - clarithromycin 500mgX2 / d The total duration of treatment is 14 days.~* If clarithromycin R: high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d- levofloxacin 500mg X2 / d The total duration of treatment is 14 days.
Study: NCT02728882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targeted CAR-T cells
Description: This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
Study: NCT04331054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2: Usual practice + SYMBICORT RAPIHALER
Description: 2 puffs bid during 30 days by inhalation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1: Usual practice
Description: Usual practice
Study: NCT03681886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmoni Modular Intraocular Lens
Description: Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmoni Modular Intraocular Lens
Description: Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optic Exchange
Description: Removal of one optic and replacement with another for the purpose of improving refractive outcomes
Study: NCT04780490

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: liberal fluid management
Description: 10 ml/ kg/ hr Ringer's lactate solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: restrictive fluid management
Description: 2 ml/ kg/ hr Ringer's lactate solution with 2 mcg / kg / hr norepinephrine infusion
Study: NCT01196533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive peripheral blood monitoring
Description: non invasive monitoring
Study: NCT01289821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Subjects will receive regorafenib 160 mg od on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets. In case of administration as a single agent during the study, regorafenib will be administered 160 mg od for 3 weeks on/1 week off. Each cycle consists of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: On day 1 and day 15 of each cycle, participants will receive 85 mg/m\^2 oxaliplatin as a 2 hour i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: On day 1 and day 15 of each cycle, participants will receive folinic acid (either 400 mg/m\^2 D/L-folinic acid or 200 mg/m\^2 L-folinic acid) as a 2 hour i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU (mFOLFOX6)
Description: Participants will receive a 400 mg/m\^2 5 FU i.v. bolus injection immediately followed by a 2400 mg/m\^2 5 FU 46 hour i.v. infusion.
Study: NCT00197808

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: menjugate
Description: men C conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Men C conjugate vaccine
Description: men C conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Men C conjugate
Description: men C conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Men C Conjugate
Description: men C conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Men C conjugate
Description: men C conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Men C conjugate
Description: men C conjugate vaccine
Study: NCT01009034

Intervention type: OTHER
Intervention: Measuring semen samples
Description: Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of maraviroc in semen, the variability in the penetration of maraviroc into the seminal compartment over the raltegravir dosing period.
Study: NCT05421962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ninety patients were included and randomized to either fentanyl-propofol (Group FP, n: 30), ketamine-propofol (Group KP, n: 30) or propofol-control group (Group C, n: 30). Group FP patients received fentanyl and propofol, Group KP received ketamine and propofol and Group C, propofol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ninety patients were included and randomized to either fentanyl-propofol (Group FP, n: 30), ketamine-propofol (Group KP, n: 30) or propofol-control group (Group C, n: 30). Group FP patients received fentanyl and propofol, Group KP received ketamine and propofol and Group C, propofol.